Free tool
FAERS Monitor: Gavreto
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214701 or its brand name (Gavreto, Pralsetinib). Reports on generic versions are filed under their own applications.
Reports
1,824
Serious
1,139
62% of reports
Hospitalization
544
Death reported
259
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product prescribing issue194
- death152
- fatigue126
- off label use120
- asthenia117
- anaemia99
- diarrhoea96
- hypertension96
- disease progression91
- blood pressure increased90
- constipation90
- white blood cell count decreased85
- pyrexia81
- pneumonia77
- platelet count decreased56
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 48 |
| 2021 | 467 |
| 2022 | 275 |
| 2023 | 179 |
| 2024 | 370 |
| 2025 | 323 |
| 2026 | 162 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,335 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product prescribing issueSignal | 194 | 103.6 | 90.6 | 19,456 |
| white blood cell count decreasedSignal | 85 | 9.0 | 7.4 | 603 |
| disease progressionSignal | 91 | 8.9 | 7.3 | 631 |
| blood pressure increasedSignal | 90 | 6.8 | 5.6 | 442 |
| platelet count decreasedSignal | 56 | 6.1 | 4.7 | 233 |
| anaemiaSignal | 99 | 6.0 | 4.9 | 410 |
| hypertensionSignal | 96 | 5.2 | 4.3 | 327 |
| constipationSignal | 90 | 4.8 | 3.9 | 266 |
| astheniaSignal | 117 | 3.6 | 3.0 | 220 |
| pneumoniaSignal | 77 | 2.7 | 2.2 | 85 |
| pyrexiaSignal | 81 | 2.7 | 2.2 | 86 |
| deathSignal | 152 | 2.0 | 1.7 | 82 |
| fatigue | 126 | 1.9 | 1.6 | 52 |
| diarrhoea | 96 | 1.7 | 1.4 | 29 |
| off label use | 120 | 1.6 | 1.3 | 26 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.